Welcome to our dedicated page for Krystal Biotech SEC filings (Ticker: KRYS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Krystal Biotech, Inc. (NASDAQ: KRYS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Krystal Biotech is a commercial-stage biotechnology company headquartered in Pittsburgh, Pennsylvania, focused on genetic medicines such as VYJUVEK for dystrophic epidermolysis bullosa and a pipeline of investigational programs in respiratory, ophthalmology, dermatology, oncology, and aesthetics.
Through this page, users can review Form 8‑K current reports in which Krystal Biotech discloses material events. Recent 8‑K filings have covered quarterly financial results, commercial launches of VYJUVEK in new markets such as Japan, regulatory approvals, and key clinical milestones, including updates on trials for KB801 in neurotrophic keratitis and KB304 in aesthetics. These filings often incorporate press releases and slide presentations by reference, providing additional context on the company’s operational and clinical progress.
In addition to 8‑K reports, investors may use this page to navigate to Krystal Biotech’s annual reports on Form 10‑K and quarterly reports on Form 10‑Q, which contain detailed information on its gene therapy platform, risk factors, financial statements, and segment information related to the development and commercialization of pharmaceutical products. For users interested in governance and compensation matters, proxy statements and related filings can also be accessed.
Stock Titan enhances these documents with AI-powered summaries that explain the key points of lengthy filings, helping readers quickly understand financial results, clinical updates, and regulatory developments without reading every page. Real-time integration with EDGAR ensures that new Krystal Biotech filings, including any future Forms 4 reporting insider transactions, 10‑Q, or 10‑K submissions, appear promptly, while AI-generated highlights point to sections that may be most relevant for KRYS shareholders and analysts.
Kathryn Romano reported sales and an intended sale of KRYS common stock. The filing shows 12,500 common shares were sold on 02/09/2026 for $3,401,705.00. It also lists 750 restricted shares tied to vesting as compensation on 02/27/2026.
KRYS reported Form 144 sales by an insider. The filing lists recent sales of Common shares by Daniel S. Janney on 02/24/2026, 02/25/2026, and 02/26/2026, including transactions of 37,895 and 13,825 shares on 02/24/2026. The entries show cash proceeds for each trade in USD.
Krystal Biotech director Daniel Janney reported option exercises and share sales in Krystal Biotech, Inc. common stock. On February 24, 2026, he exercised stock options covering 37,895 shares and received the same number of common shares, then sold those shares in multiple open-market transactions.
On February 24 and 26, 2026, additional open-market sales were reported in accounts indirectly holding shares for Alta Bioequities, L.P., which is managed by an affiliated general partner. The filing notes that Janney’s option exercise and sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 25, 2025. After these trades, 85,096 shares were held indirectly through Alta Bioequities, L.P., while no shares were held directly.
KRYS affiliate files Form 144 to sell common stock. The filing lists proposed/reported sales by Daniel S. Janney consisting of 37,895 shares, 13,825 shares and 700 shares with aggregate cash proceeds reported as $10,113,354.42, $3,709,850.15 and $192,500, respectively. Dates shown for the transactions are 02/24/2026 and 02/25/2026.
KRYS filing a Form 144 notice reports proposed sales of common stock by Daniel S. Janney. The filing lists a proposed sale of 37,895 shares for $10,113,354.42 and a proposed sale of 13,825 shares for $3,709,850.15, both dated 02/24/2026.
KRYS submitted a Form 144 notifying a proposed sale of Common stock, listing 37,895 shares to be sold through Fidelity Brokerage Services LLC by 02/24/2026 with a sale method labeled Cash.
The filing also shows securities sold during the past three months: 13,825 Common shares by Daniel S. Janney on 02/24/2026 for $3,709,850.15.
KRYS: Form 144 sale notice by Daniel S Janney for $10,113,354.42 proceeds on 02/24/2026. The filing lists the sale of 37,895 common shares and identifies the issuer contact as Merrill Lynch, 555 California Street, San Francisco. The securities trace to a private placement dated 08/25/2017.
Krystal Biotech, Inc. director Dino A. Rossi reported option exercises and related share sales. On February 19, 2026, he exercised stock options for 18,950 shares of common stock at $8.79 per share. The options vested ratably over four years beginning on June 1, 2018. On the same date, he sold 8,116 shares at $260.4858 and 10,834 shares at $262.10 in open-market transactions, totaling 18,950 shares sold. After these trades, he directly owned 78,691 shares of Krystal Biotech common stock.
Krystal Biotech reported strong fourth quarter and full year 2025 results, with full-year product revenue, net of $389.1 million and net income of $204.8 million, or $6.84 per diluted share. Fourth quarter product revenue reached $107.1 million, driving quarterly net income of $51.4 million, or $1.70 per diluted share. The company ended December 31, 2025 with $955.9 million in cash, cash equivalents, and investments, and generated a gross margin of 94% on VYJUVEK revenue. Krystal also highlighted global commercialization progress for VYJUVEK and advancement across its respiratory, ophthalmology, dermatology, oncology, and aesthetics pipelines, including FDA RMAT and Fast Track designations and multiple ongoing or planned registrational studies.